欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (11): 1226-1230.

• 研究原著 • 上一篇    下一篇

固相萃取HPLC检测生物样品中甲苯磺丁脲和代谢产物及其人体药代动力学研究

王睿, 陈騉1   

  1. 解放军总医院临床药理研究室,北京 100853;
    1中国海洋大学,青岛 266003,山东
  • 收稿日期:2004-09-15 接受日期:2004-10-23 出版日期:2004-11-26 发布日期:2020-11-19

HPLC assay for tolbutamide and its metabolites in biological sample by solid phase extraction and study of its pharmacokinetics in human

WANG Rui, CHEN Kun1   

  1. Department of Clinical Pharmacology, Chinese PLA General Hospital, Beijing 700853, China;
    1Marin Drug & Food Institute, Ocean University of Chirm, Qingdao 266003, Shangdong, China
  • Received:2004-09-15 Accepted:2004-10-23 Online:2004-11-26 Published:2020-11-19
  • Contact: WANG Rui, Female, Master, Doctor Director, Engaged in Clinical Pharmacology.Tel: 010-66937909 E-mail: wangrui301@95777.com
  • Supported by:
    Supported by the State 863 High Technology Project of China (No2002AA2Z3411)

摘要: 目的: 建立固相萃取高效液相色谱测定人血浆和尿液中的甲苯磺丁脲和代谢产物浓度的方法,并用于研究甲苯磺丁脲人体代谢过程。方法: 固相萃取净化和富集样品,建立高效液相色谱法测定人血清和尿中曱苯磺丁脲和代谢产物的浓度。色谱条件:色谱柱为 Waters Spherisorb 5 μm Phenyl 色谱柱(4.6 mm×250 mm),流动相为甲醇-0.02mmol·L-1 pH 3.3乙酸钠缓冲液(28:72),流速1 ml·min-1,检测波长:230 nm。用该方法测定10名健康志愿者单次口服500 mg曱苯磺丁脲后血清和尿液中药物及其代谢产物浓度,应用3p97计算其的药动学参数。结果: 血浆曱苯磺丁脲线性范围为2~lOOμmol·L-1 (r=0.999),回收率为105.1%~103.9%。尿液羧基曱苯磺丁脲、4-羟基甲苯磺丁脲和甲苯磺丁脲的线性范围为 2~50 μmol·L-1 (r=0.999)、1~50 μmol·L-1 (r=0.999)和 1~50 μmol·L-1 (r=0.999),回收率为 98.8%~100.1%、95.4%~103.5%和97.7%~106.6%。各样品的日内、日间精密度均矣15%。健康志愿者单次口服500 mg甲苯磺丁脲的 AUC0-∞ 为 2644.6±472.8 μmol·h-1·L-1,Tmax是 1.4±0.6 h,Cmax是235.8±47.3 μmol·L-1,t1/2为 6.9±2.1 h,MR0-24=277.5±125.6。结论: 甲苯磺丁脲及其代谢产物的固相萃取高效液相色谱法灵敏、准确,重复性好,可用于甲笨磺丁脲的体内过程研究。甲苯磺丁脲代谢产物主要经尿液排出。

关键词: 固相萃取, 高效液相色谱, 甲苯磺丁脲, 药代动力学

Abstract: AIM: To establish a HPLC method by solid-phase extraction which was used for determining tol-butamide and its metabolites in human plasma and urine, and to study its pharmacokinetics. METHODS; The concentrations of tolbutamide and its metabolites in human plasma and urine by solid-phase extraction were deter-mined by HPLC. Watere Spherisorb 5 μm Phenyl column (4.6 mm×250 mm) was used as the analytical column and the mobile phase was consisted by methanol-0.02 mmol·L-1 pH 3.3 Na2Ac buffer(28:72). The flow rate was 1 ml·min-1 and UV detection wavelength was 230 nm. The concentrations of tolbutamide and its metabolites in plasma and urine in healthy volunteers were determined by HPLC and the pharmacokinetic parameters were ana-lyzed by 3p97. RESULTS: The linear range was 2-100 μmol·L-1 (r=0.999) for tolbutamide in human plasma by solid phase extraction. The recovery was 105.1%-103.9%. The linear range was 2-50 μmol·L-1 (r=0.999) for carboxytolbutamide in human urine. The recovery was 98.8%-100.1%. The linear range was 1-50 μmol·L-1 (r=0.999) for 4-hydroxytolbutamide in human urine. The recovery was 95.4%-103.5%. The linear range was 1-50 μmol·L-1 (r=0.999) for tolbu-tamide in human urine. The recovery was 97.7%-106.6%. The within-day and between-day derivations of all samples were less than 15%. A single oral dose of 500 mg tolbutamide was administrated to the volunteers, the main pharmacokinetic parameters AUC0-∞, t1/2, Tmax, Cmax, and MR0-24 were 2644.6±472.8 μmol·h-1·L-1, 1.4±0.6 h,235.8±47.3 μmol·L-1 and 277.5±125.6, respectively. CONCLUSION: The method is simple and accurate, and it can be used determining tolbutamide and its metab-olites in biological samples. Tolbutamide is mainly excret-ed through urine in form of carboxytolbutamide and hydroxytolbutamide.

Key words: solid phase extraction, HPLC, tolbu-tamide, pharmacokinetics

中图分类号: